Table 4 Comparison of published real-world comparative studies between ranibizumab and aflibercept.
Study | Country | Data source | Treatment | Subjects | Numbers of subjects (eyes) | Regimen | Study period | Age of subjects (years) | Baseline VA | VA change from baseline | Mean number of injections | Conclusion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gilles et al.10 | Australia, New Zealand, Switzerland | FRB! registry | RBZ, AFL | Treatment-naïve eyes | 394 (197 RBZ, 197 AFL) | Monthly, PRN, or T&E | 12 months | 81.1 [RBZ] vs. 79.9 [AFL] | 58.6 [RBZ] vs. 58.9 [AFL] letters | + 3.7 [RBZ] vs. + 4.26 [AFL] letters | 8.1 [RBZ] vs. 8.0 [AFL] | Similar efficacy and treatment pattern |
Lotery et al.11 | US | Standardized US EMR system | RBZ, AFL | Excluded eyes received anti-VEGF within 6 months | 7650 (3350 RBZ, 4300 AFL) | N/A | 12 months | 83.4 [RBZ] vs. 82.4 [AFL] | 57.5 [RBZ] vs. 58.5 [AFL] letters | − 0.30 [RBZ] vs. − 0.19 [AFL] letters | 6.7 [RBZ] vs. 7.0 [AFL] | Similar efficacy and treatment pattern |
Rao et al.13 | US | AAO IRIS registry | RBZ, AFL, BVZ | Eyes received anti-VEGF within 12 months were excluded | 13,859 (2749 RBZ, 4387 AFL, 6723 BVZ) | N/A | 12 months | 81.4 [RBZ] vs. 80.5 [AFL] vs. 80.9 [BVZ] | 0.54 [RBZ] vs. 0.53 [AFL] vs. 0.61 [BVZ] | − 0.053 [RBZ] vs. − 0.040 [AFL] vs. − 0.048 [BVZ] logMAR | 6.5 [RBZ] vs. 6.2 [AFL] vs. 5.9 [BVZ] | Similar efficacy; fewer injections in BVZ than RBZ and AFL |
Bhandari et al.12 | Australia, New Zealand, Switzerland | FRB! registry | RBZ, AFL | Treatment-naïve eyes | 965 (499 RBZ, 466 AFL) | N/A | 3 years | 82 [RBZ] vs. 79 [AFL] | 59.9 [RBZ] vs. 58.2 [AFL] letters | + 4.6 [RBZ] vs. + 4.5 [AFL] letters at 2 years; + 1.5 [RBZ] vs. + 1.6 [AFL] letters at 3 years | median 18 [RBZ] vs. median 18 [AFL] (total 3 years) | Similar efficacy and treatment pattern |
Present study (Bundang AMD cohort study 4) | South Korea | EMR chart review from multicenter, matched-cohort | RBZ, AFL | Treatment-naïve eyes | 215 (131 RBZ, 84 AFL) | PRN or T&E | 4 years | 69.8 [RBZ] vs. 70.6 [AFL] | 53.0 [RBZ] vs. 52.5 [AFL] letters | + 6.7 [RBZ] vs. + 2.6 [AFL] letters at 1 year; + 2.1 [RBZ] vs. − 0.4 [AFL] letters at 2 year, − 1.3 [RBZ] vs. − 1.8 [AFL] letters at 3 years; − 2.2 [RBZ] vs. − 5.0 [AFL] letters at 4 years | 4.1 [RBZ] vs. 4.5 [AFL] for 1 year; Mean 2.9 [RBZ] vs. 3.0 [AFL] during 4 years | Similar efficacy and treatment pattern in nAMD and PCV |
